CytRx To Start Phase 2 Clinical Trial Of INNO-206
CytRx is going to initiate an open-label, multinational phase 2 clinical trial with its doxorubicin prodrug INNO-206, as a second-line treatment in patients with advanced gastric (stomach) cancer.
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
Under these licensing agreements, EraGen will have access to Illumina’s BeadXpress platform for the continued development and commercialisation of molecular-based, high-throughput clinical multiplexed assays with its unique, patented